UAE News Online
Main » 2017 » August » 14
VILLEJUIF, France -Thursday, August 10th 2017 [ AETOS Wire ] (BUSINESS WIRE)-- WIN Consortium (WIN) received the US Food and Drug Administration (FDA)’s approval to start the clinical investigation of a novel therapeutic approach using a combination of three targeted therapies for the first line treatment of patients with advanced Non Small Cell Lung Cancer (NSCLC). The Survival Prolongation by Rationale Innovative Genomics (SPRING) trial will aim to enroll patients who are usually offered first line platinum-based chemotherapy. Patients with documented targetable driver alterations (EGFR mutations, ALK rearrangements, ROS1 and MET exon 14 skipping mutations) will be excluded. The population of NSCLC patients without actionable oncogenic driver mutations, envisioned for the enrollment in SPRING trial, represents the vast majority of patients with metastatic NSCLC (~80% in the Caucasian population). With over 60% of NSCLC detected in an advanced or metastatic stage, and less than 5% o ... Read more »
Views: 191 | Added by: uaeonlinenews | Date: 08.14.2017